Avalyn Pharma Inc.

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled medicines for rare respiratory diseases, such as pulmonary fibrosis and other interstitial lung diseases. The company's approach involves delivering inhaled formulations of existing oral medicines directly to the lungs. Its current development pipeline is concentrated on treating pulmonary fibrosis. Key products in its pipeline include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib, respectively, designed for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. Additionally, Avalyn Pharma Inc. is developing AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib, intended to provide dual antifibrotic mechanisms. The company was incorporated in 2011 and is headquartered in Boston, Massachusetts. It was previously known as Genoa Pharmaceuticals, Inc. and adopted the name Avalyn Pharma Inc. in July 2017.